303 Results for "

Histone H3

" in MedChemExpress (MCE) Product Catalog:
Products (303)

303 Results for "Histone H3" in MCE Product Catalog:

54
54 Publications Verification
Cat. No.: HY-123606
CAS No.: 1652629-23-6
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-16993
CAS No.: 1801787-56-3
Target:  

Apoptosis WDR5

Research Areas:  

Cancer

OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-18935
CAS No.: 1197996-80-7
Synonyms: Curaxin 137; CBL-C137
Research Areas:  

Cancer

CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-129039
CAS No.: 778649-18-6
Purity:  99.58%
Synonyms: MB-3
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC50=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC50=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12970
CAS No.: 1700663-41-7
Purity:  98.07%
EPZ020411 is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12970A
CAS No.: 2070015-25-5
Purity:  98.15%
EPZ020411 hydrochloride is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 hydrochloride blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 hydrochloride is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-102047B
CAS No.: 2448475-08-7
Purity:  98.11%
Target:  

Histone Demethylase

Research Areas:  

Cancer

KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15217
CAS No.: 1333377-65-3
Purity:  96.71%
Target:  

Haspin Kinase

Research Areas:  

Cancer

CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-120400
CAS No.: 1596348-32-1
Purity:  97.08%
Target:  

Histone Demethylase

Research Areas:  

Cancer

KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12583
CAS No.: 1527503-11-2
Purity:  98.01%
A-366, a chemical probe, is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC50=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (Ki=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-141539
CAS No.: 2755823-12-0
Purity:  99.93%
Research Areas:  

Cancer

SETDB1-TTD-IN-1 is a SETDB1 methyltransferase activator and SETDB1-TTD competitive inhibitor (Kd of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes Akt1 Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-16705
CAS No.: 1374601-40-7
Research Areas:  

Cancer

BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC50 of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-13808
CAS No.: 1320288-19-4
Purity:  99.27%
Research Areas:  

Cancer

UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC50 of 4 nM. UNC 0631 potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 25 nM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-100014
CAS No.: 1905481-36-8
Purity:  99.64%
Target:  

Histone Demethylase

Research Areas:  

Cancer

KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12220
CAS No.: 1417329-24-8
Purity:  99.39%
Synonyms: HMTase Inhibitor IX
MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC50=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P80166

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, IP, ChIP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W013274
CAS No.: 357649-93-5
Research Areas:  

Cancer

CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1941
CAS No.: 140-66-9
4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic agent. 4-tert-Octylphenol is also a biodegradation product of non-ionic surfactants alkylphenol polyethoxylates. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice, which is promising for reserch of immune response, neuro-related diseases and ethology .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16531
CAS No.: 1311423-89-8
Research Areas:  

Neurological Disease Cancer

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16531A
CAS No.: 1312005-62-1
Research Areas:  

Neurological Disease Cancer

YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .
loading...
    loading...